INFO & CONTACTS:  +39 02 2390 1

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy

Phase: Phase II-III clinical trials

Principal Investigator: Dott. Procopio Giuseppe

Main Facility: Oncologia Medica Genitourinaria

Drug: Opevesostat (MK-5684) + hormone replacement therapy (HRT) // abiraterone acetate or enzalutamide

Pathologies: Prostate tumors

Eligible participants will be randomly assigned in a 1:1 ratio to receive treatment with either MK-5684 plus HRT or alternative abiraterone acetate or enzalutamide. Randomization will be stratified according to the participants measurable disease (yes vs no), AR LBD mutation status (yes vs no) and prior cabazitaxel treatment (yes vs no).

Last update: 21/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe